Antibiotics

Genomenon Acquires The Jackson Laboratory's Clinical Knowledgebase (CKB) to Fuel its Mission to Curate the Human Genome

Retrieved on: 
星期三, 五月 8, 2024
Cancer, Genomics, Jackson Laboratory, ANN, CKB, JAX, Acquisition, Mouse, Database, Genome, Medicine, Growth, Antibiotics

ANN ARBOR, Mich., May 8, 2024 /PRNewswire-PRWeb/ -- Genomenon, a genomic intelligence company today announced its acquisition of the Clinical Knowledgebase (CKB) from The Jackson Laboratory (JAX). CKB is the leading curated variant database used for interpreting complex cancer genomic profiles by some of the world's premier oncology labs. This strategic acquisition enables Genomenon to provide an unprecedented understanding of the genome, with insights now covering both germline and somatic variants, furthering its lead in the race to curate the genome. Financial terms of the acquisition were not disclosed.

Key Points: 
  • This strategic acquisition enables Genomenon to provide an unprecedented understanding of the genome, with insights now covering both germline and somatic variants, furthering its lead in the race to curate the genome.
  • "The acquisition of CKB is a significant step in Genomenon's mission to curate the entire human genome," shared Mike Klein, CEO of Genomenon.
  • "The acquisition of CKB is a significant step in Genomenon's mission to curate the entire human genome," shared Mike Klein, CEO of Genomenon.
  • In June 2023, Genomenon announced the acquisition of Boston Genetics as part of its mission to curate the human genome.

HER HIGHNESS SHEIKHA MOZA FORMALLY LAUNCHES QATAR PRECISION HEALTH INSTITUTE

Retrieved on: 
星期三, 五月 1, 2024
Disorder, Genetics, Genomics, Global Alliance, Map, Qatar Genome Programme, Heart, Research, Parent, Qatar Foundation, Environment, Patient, Arab world, Multimedia, Medicine, Antibiotics

DOHA, Qatar, May 1, 2024 /PRNewswire/ -- Her Highness Sheikha Moza bint Nasser, Chairperson of Qatar Foundation, officially launched the Qatar Precision Health Institute, a national body aimed at leveraging the country's advanced genomics research to accelerate personalized healthcare – leading to more precise treatments and improved health outcomes for people in the Arab world and beyond.

Key Points: 
  • DOHA, Qatar, May 1, 2024 /PRNewswire/ -- Her Highness Sheikha Moza bint Nasser, Chairperson of Qatar Foundation, officially launched the Qatar Precision Health Institute, a national body aimed at leveraging the country's advanced genomics research to accelerate personalized healthcare – leading to more precise treatments and improved health outcomes for people in the Arab world and beyond.
  • The Qatar Precision Health Institute builds on the groundbreaking work of Qatar Biobank and Qatar Genome Programme, uniting the efforts of Qatar Foundation's research institutes to provide insights that reveal the effects of lifestyle, environment, and genetics on the Arab population.
  • Her Highness, Sheikha Moza bint Nasser, spoke at the formal launch event, emphasizing the importance of raising public awareness on the benefits of precision health.
  • Qatar Foundation's work in the field of precision health led to the creation of the Qatari genome catalog, comprising more than 88 million variants, 24 million of which had never been reported previously in international databases.

HER HIGHNESS SHEIKHA MOZA FORMALLY LAUNCHES QATAR PRECISION HEALTH INSTITUTE

Retrieved on: 
星期三, 五月 1, 2024
Disorder, Genetics, Genomics, Global Alliance, Map, Qatar Genome Programme, Heart, Research, Parent, Qatar Foundation, Environment, Patient, Arab world, Medicine, Antibiotics

DOHA, Qatar, May 1, 2024 /PRNewswire/ -- Her Highness Sheikha Moza bint Nasser, Chairperson of Qatar Foundation, officially launched the Qatar Precision Health Institute, a national body aimed at leveraging the country's advanced genomics research to accelerate personalized healthcare – leading to more precise treatments and improved health outcomes for people in the Arab world and beyond.

Key Points: 
  • DOHA, Qatar, May 1, 2024 /PRNewswire/ -- Her Highness Sheikha Moza bint Nasser, Chairperson of Qatar Foundation, officially launched the Qatar Precision Health Institute, a national body aimed at leveraging the country's advanced genomics research to accelerate personalized healthcare – leading to more precise treatments and improved health outcomes for people in the Arab world and beyond.
  • The Qatar Precision Health Institute builds on the groundbreaking work of Qatar Biobank and Qatar Genome Programme, uniting the efforts of Qatar Foundation's research institutes to provide insights that reveal the effects of lifestyle, environment, and genetics on the Arab population.
  • Her Highness, Sheikha Moza bint Nasser, spoke at the formal launch event, emphasizing the importance of raising public awareness on the benefits of precision health.
  • Qatar Foundation's work in the field of precision health led to the creation of the Qatari genome catalog, comprising more than 88 million variants, 24 million of which had never been reported previously in international databases.

Jaya Biosciences Presents Updated Preclinical Data in Alzheimer’s Disease at the 45th SIMD Annual Meeting

Retrieved on: 
星期二, 四月 16, 2024
GUSB, Society, PPT1, IDUA, Haploinsufficiency, Gene dosage, Central Waqf Council, Animal, GALC, Research, AAV, IND, CNS, Disease, Science, NAGLU, Patient, DSM-IV codes, SIMD, Toxicology, Annual general meeting, Plaque, SAN, Gene, APP, Antibiotics

During a podium presentation, Jaya Biosciences’ scientific founder and science advisory board chair, Professor Mark Sands, reported on recently updated human genetic analyses suggesting that heterozygous loss-of-function mutations in lysosomal enzyme genes are enriched in Alzheimer’s disease (AD) patients.

Key Points: 
  • During a podium presentation, Jaya Biosciences’ scientific founder and science advisory board chair, Professor Mark Sands, reported on recently updated human genetic analyses suggesting that heterozygous loss-of-function mutations in lysosomal enzyme genes are enriched in Alzheimer’s disease (AD) patients.
  • This new analysis generated from a much larger whole genome sequence database confirmed their previous human genetic findings from a smaller whole exome database.
  • “The updated human genetic data confirmed that heterozygous deleterious mutations in a subset of lysosomal genes are enriched in patients with Alzheimer’s disease,” said Prof. Mark Sands.
  • For more information about the 45th SIMD Annual Meeting, please go to SIMD2024 Meeting .

Nobel Laureate Thomas Südhof and bit.bio CEO Mark Kotter to Lead Fireside Chat on Programming Human Cells at SynBioBeta

Retrieved on: 
星期一, 四月 29, 2024
Research, Neurology, Genetics, Stem Cells, Biotechnology, Health, Pharmaceutical, General Health, Science, Factorization of polynomials, Stanford University, University, Genetic code, VIP, B cell, Engineering, Patient, Synthetic biology, Biology, Genomics, Drug discovery, Therapy, San Jose Convention Center, Antibiotics

bit.bio, the company coding human cells for novel cures, and a pioneer in the field of synthetic biology, today announces it will participate in an engaging fireside chat at SynBioBeta 2024 featuring Nobel Laureate Thomas Südhof and bit.bio founder Mark Kotter.

Key Points: 
  • bit.bio, the company coding human cells for novel cures, and a pioneer in the field of synthetic biology, today announces it will participate in an engaging fireside chat at SynBioBeta 2024 featuring Nobel Laureate Thomas Südhof and bit.bio founder Mark Kotter.
  • The fireside chat will explore how the new paradigm of cell programming, combined with our ability to read, write and execute genetic code, opens unprecedented opportunities for improving human health.
  • Südhof’s groundbreaking work on cell programming represents a paradigm shift in biology,” said Dr. Mark Kotter, CEO of bit.bio.
  • "The fireside chat between Thomas Südhof and Mark Kotter exemplifies the meeting of inquisitive minds and revolutionary ideas in the field of synthetic biology,” said John Cumbers , founder and CEO of SynBioBeta.

Orchard Software Announces New Electronic Support for Antimicrobial Stewardship

Retrieved on: 
星期四, 四月 25, 2024
NHSN, Public health, Hospital, CDC, Antimicrobial stewardship, Data analysis, Infection, Orchard, Antibiotics

Orchard's solutions send the required data to EMRs to support regulatory requirements and antimicrobial stewardship endeavors.

Key Points: 
  • Orchard's solutions send the required data to EMRs to support regulatory requirements and antimicrobial stewardship endeavors.
  • AUR reporting and data analysis promotes antimicrobial stewardship and impedes the transmission of resistant pathogens.
  • "At Orchard, we are continually looking for ways to support our customers and the valuable work they do.
  • Support for AUR reporting is one more way that we can provide superior support to our customers," said Billie Whitehurst, CEO of Orchard Software.

Eurofins Genomics AgriGenomics Europe and Gencove announce collaboration to offer complete solution for low-pass whole genome sequencing

Retrieved on: 
星期二, 四月 9, 2024
Agriculture, Partnership, DNA, SNP, Doctor of Philosophy, Genomics, Aquaculture, Antibiotics

New York, USA and Galten, Denmark, April 09, 2024 (GLOBE NEWSWIRE) -- Eurofins Genomics AgriGenomics Europe, an internationally leading provider of DNA sequencing and genotyping services and Gencove, a pioneer of low-pass whole genome sequencing (lpWGS) imputation and analysis, today announced a partnership to offer a complete solution for lpWGS in Europe, delivering high-throughput and cost-effective sequencing.

Key Points: 
  • New York, USA and Galten, Denmark, April 09, 2024 (GLOBE NEWSWIRE) -- Eurofins Genomics AgriGenomics Europe, an internationally leading provider of DNA sequencing and genotyping services and Gencove, a pioneer of low-pass whole genome sequencing (lpWGS) imputation and analysis, today announced a partnership to offer a complete solution for lpWGS in Europe, delivering high-throughput and cost-effective sequencing.
  • The partnership will combine Gencove’s platform for data analytics and management with Eurofins Genomics AgriGenomics Europe’s capabilities running low-pass whole genomics sequencing to usher in a new era in genotyping.
  • The collaboration leverages both companies' strengths in sequencing to accelerate advancements in genotyping benefiting plant breeders, livestock selectors, aquaculture, and companion animal sectors.
  • In making large-scale genomic information more accessible and actionable, Gencove and Eurofins Genomics AgriGenomics Europe are setting new benchmarks for what is possible in agriculture.

S2 Genomics Announces Groundbreaking Single Cell FFPE Sample Prep Isolation Product

Retrieved on: 
星期二, 四月 9, 2024
Chemicals, Plastics, Electronic Design Automation, Manufacturing, Technology, Stem Cells, Pharmaceutical, Oncology, Medical Devices, Genetics, Clinical Trials, Other Manufacturing, Other Technology, Biotechnology, Science, Research, Health, Genomics, Tissue, RNA, The central science, Antibiotics

S2 Genomics, a pioneer in tissue sample preparation systems, today announced the launch of its latest product, the Singulator™ 200+ System, an automated sample prep isolation system for single cell formalin-fixed, paraffin-embedded (FFPE) tissues.

Key Points: 
  • S2 Genomics, a pioneer in tissue sample preparation systems, today announced the launch of its latest product, the Singulator™ 200+ System, an automated sample prep isolation system for single cell formalin-fixed, paraffin-embedded (FFPE) tissues.
  • The new FFPE sample prep isolation system is designed to isolate nuclei from FFPE tissue slices, enabling single-nucleus RNA sequencing (snRNA-Seq) for FFPE samples.
  • Jonathan Schimmel, President and CEO of S2 Genomics, expressed his enthusiasm for the new product: “The FFPE sample prep isolation system is a testament to our commitment to continuing innovation and excellence in the field of single cell genomics.
  • For more information about the FFPE sample prep isolation system and other S2 Genomics products, please visit us at s2genomics.com or connect with us on LinkedIn or Twitter .

Recce Pharmaceuticals Announces RECCE® Trademark Registered in Canada, Strengthening Global IP Portfolio

Retrieved on: 
星期五, 三月 22, 2024
ASX, RCE, Canada Revenue Agency, AMR, Science, IP, Infection, Antibiotics

SYDNEY, Australia, March 22, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced it has been issued a trademark registration for RECCE® from the Canadian Intellectual Property Office, strengthening its global intellectual property (IP) portfolio.

Key Points: 
  • SYDNEY, Australia, March 22, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced it has been issued a trademark registration for RECCE® from the Canadian Intellectual Property Office, strengthening its global intellectual property (IP) portfolio.
  • 1289603 formally assigns RECCE® the Canada Trademark No.
  • “We are pleased to receive this newly registered trademark in Canada, building upon those already registered in the world’s largest pharmaceutical markets,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • The Canada Revenue Agency administers the program, aiming to incentivize businesses to conduct R&D in Canada, encouraging innovation and technological advancements.

Inocras Inc. Unveils Rebranding of Genome Insight

Retrieved on: 
星期一, 三月 18, 2024
Technology, Neurology, Genetics, Biotechnology, Other Health, Health, Data Management, Artificial Intelligence, Oncology, Disease, Patient, Research, Cancer, AI, CAP, CLIA, Whole genome sequencing, Nursing care plan, Antibiotics

Inocras, formerly known as Genome Insight, announced today its rebranding initiative to reflect its commitment to innovation and user-centric healthcare solutions.

Key Points: 
  • Inocras, formerly known as Genome Insight, announced today its rebranding initiative to reflect its commitment to innovation and user-centric healthcare solutions.
  • The AI-driven whole genome platform company, specialized in whole genome sequencing and analytics for cancer and rare diseases, has embarked on its rebranding to reinforce its dedication to shaping an "innovative tomorrow".
  • The rebranding accentuates its focus on "user-centric approaches" for patients, providers, and researchers, surpassing the provision of sequencing and analytics services.
  • Inocras Inc. (formerly Genome Insight Inc.) is a pioneering provider of whole genome sequencing and analytics services for cancer and rare diseases.